Adalimumab-Adaz(Cf) Pen (Adalimumab-Adaz) Patent Expiration, LOE Window & CMS Spending

Adalimumab-Adaz(Cf) Pen (Adalimumab-Adaz) by Sandoz: Off-Patent Genericized (AB Competition), 0 AB generics, $13.5M 2024 CMS Part D & Medicaid spend, and $2,631 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSandoz
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$13.5M
2024 Medicare Part D Spend$4.7M
2024 Medicaid Spend$8.9M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,631 intro WAC)